About: ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.09 (+3.81%)
ABVC NASDAQ ABVC Biopharma Inc
ABVC Biopharma Inc share price
Atividade de preço de ABVC
Último preço
$ 1,090
Variação (24h)
0,04 USD (3,81%)
Volume
35.23K
Volume (média 4 sem.)
-
Abertura
$ 1,05
Variação do dia
$ 1,03 - $ 1,09
Fechamento anterior
$ 1,05
Último negócio
28 Oct, 8:00 pm GMT+0
Atrasado
28 Oct, 8:00 pm GMT+0
ABVC price performance
Atrasado
28 Oct, 8:00 pm GMT+0
quote.marketSignals